Abstract
Background: Long non-coding RNAs are critical to hepatocellular carcinoma (HCC) developments. LncRNA PITPNA antisense RNA 1 (PITPNA-AS1) is a new regulator in several tumors. However, the mechanism by which PITPNA-AS1 mediates the tumorigenesis of HCC remains unclear. Methods: RT-qPCR was used to detect the level of PITPNA-AS1 in HCC specimens and cells. The biological functions of PITPNA-AS1 were explored by several functional experiments in vivo and in vitro. The binding relationship among PITPNA-AS1, miR-448 and ROCK1 were studied by Luciferase assay and pull-down assays. Results: We found that PITPNA-AS1 expressions were distinctly upregulated in both HCC specimens and cell lines. High PITPNA-AS1 levels were an unfavorable biomarker for patients with HCC. Functionally, knockdown of PITPNA-AS1 suppressed the proliferation, migration and invasion of HCC cells. Mechanistically, PITPNA-AS1 functioned as competing endogenous RNA to increase ROCK1 expressions via sponging miR-448. Conclusion: The newly identified PITPNA-AS/miR-448/ROCK1 axis promoted the oncogenicity of HCC cells. This novel axis is likely to be a promising HCC therapeutic aim.
Introduction
Hepatocellular Carcinoma (HCC) remains the second leading cause of cancer-related mortality worldwide. Despite advancements in surgical techniques and diagnostic tools, long-term survival is often compromised by high rates of recurrence and metastasis, which can reach 45–65% within five years. Recent research has pivoted toward the "dark matter" of the genome—non-coding RNAs—to uncover new regulatory mechanisms. Long non-coding RNAs (lncRNAs), while not protein-coding, are pivotal regulators of gene expression. PITPNA-AS1 has been implicated in other malignancies, but its role in HCC progression and its underlying molecular axis remained largely unexplored until this study.
Materials and Methods
The researchers employed a comprehensive multi-disciplinary strategy:
- Expression Profiling: RT-qPCR quantified PITPNA-AS1 levels in 93 pairs of HCC and adjacent normal tissues, alongside various liver cancer cell lines (Hep3B, HepG2, SMMC-7721, HCCLM3) and a normal control (L02).
- Functional Characterization: Short hairpin RNA (shRNA) was used to knock down PITPNA-AS1. Subsequent assays measured cell proliferation (CCK-8, colony formation), migration (wound healing), and invasion (Transwell).
- Mechanistic Validation: Luciferase reporter and RNA pull-down assays were conducted to confirm the physical interaction between PITPNA-AS1, miR-448, and ROCK1.
- In Vivo Models: Xenograft studies in nude mice evaluated the impact of PITPNA-AS1 silencing on tumor growth over a 28-day period.
Results
PITPNA-AS1 is Significantly Upregulated in HCC
Analysis of the clinical cohort revealed that PITPNA-AS1 expression is markedly higher in tumor tissues compared to matched normal tissues. This finding was consistent across multiple bioinformatics datasets, including TCGA.
Clinical Significance and Survival Outcomes
High expression of PITPNA-AS1 was statistically correlated with larger tumor size, advanced clinical stages (III-IV), and poor prognosis. Kaplan-Meier analysis demonstrated that patients with high PITPNA-AS1 levels had significantly shorter overall survival (OS) and disease-free survival (DFS).
The PITPNA-AS1/miR-448/ROCK1 Axis
The study identified PITPNA-AS1 as a competing endogenous RNA (ceRNA). In healthy liver cells, miR-448 typically suppresses the expression of the oncogenic protein ROCK1. However, in HCC, overexpressed PITPNA-AS1 acts as a "molecular sponge," sequestering miR-448. This sequestration prevents miR-448 from binding to ROCK1 mRNA, leading to increased ROCK1 levels and subsequent promotion of tumor growth, migration, and invasion.
Discussion and Conclusion
This research successfully maps the PITPNA-AS1/miR-448/ROCK1 axis as a driver of HCC progression. The diagnostic potential of PITPNA-AS1 is supported by an ROC curve AUC of 0.7810. While the study provides strong evidence for this pathway, future work should involve larger multi-center cohorts and explore the therapeutic delivery of anti-sense oligonucleotides to target this lncRNA in clinical settings. In conclusion, PITPNA-AS1 represents a promising biomarker and a potential therapeutic target for improving outcomes in patients with HCC.
Summary updated